Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frontline Antibiotics for HP-negative Gastric MALT Lymphoma
NCT07144657Phase 2Not yet recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Sep 2025
- Primary completion
- Dec 2029
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of clarithromycin, cyclophosphamide, bismuth subcitrate, tetracycline, metronidazole in gastric mucosa-associated lymphoid tissue lymphoma, sponsored by National Taiwan University Hospital. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
clarithromycincyclophosphamidebismuth subcitratetetracyclinemetronidazole
03
Conditions
gastric mucosa-associated lymphoid tissue lymphoma
Beyond the preview
Go deeper on NCT07144657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07144657.